CN1141093C - 番荔枝内酯抗癌有效部位药及其制备方法 - Google Patents
番荔枝内酯抗癌有效部位药及其制备方法 Download PDFInfo
- Publication number
- CN1141093C CN1141093C CNB011075945A CN01107594A CN1141093C CN 1141093 C CN1141093 C CN 1141093C CN B011075945 A CNB011075945 A CN B011075945A CN 01107594 A CN01107594 A CN 01107594A CN 1141093 C CN1141093 C CN 1141093C
- Authority
- CN
- China
- Prior art keywords
- anticancer
- arnold
- lectone
- lichee
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 35
- 150000002596 lactones Chemical class 0.000 claims abstract description 58
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 239000003208 petroleum Substances 0.000 claims abstract description 21
- 239000003960 organic solvent Substances 0.000 claims abstract description 16
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 25
- 238000000605 extraction Methods 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 22
- 239000000741 silica gel Substances 0.000 claims description 21
- 229910002027 silica gel Inorganic materials 0.000 claims description 21
- 229960001866 silicon dioxide Drugs 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 238000004809 thin layer chromatography Methods 0.000 claims description 16
- 239000002026 chloroform extract Substances 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 7
- 238000007689 inspection Methods 0.000 claims description 7
- 238000005238 degreasing Methods 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 11
- 241001081440 Annonaceae Species 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 5
- 235000013336 milk Nutrition 0.000 abstract description 4
- 239000008267 milk Substances 0.000 abstract description 4
- 210000004080 milk Anatomy 0.000 abstract description 4
- 238000003908 quality control method Methods 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- -1 and firstly Substances 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 4
- 238000011047 acute toxicity test Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- DAEFUOXKPZLQMM-UHFFFAOYSA-N squamocin A Natural products O1C(C(O)CCCC(O)CCCCCC)CCC1C1OC(C(O)CCCCCCCCCCCCC=2C(OC(C)C=2)=O)CC1 DAEFUOXKPZLQMM-UHFFFAOYSA-N 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 201000006845 reticulosarcoma Diseases 0.000 description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 3
- 244000028821 Annona squamosa Species 0.000 description 2
- 235000005274 Annona squamosa Nutrition 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- DAEFUOXKPZLQMM-AUDZWCKFSA-N Squamocin Chemical compound O1[C@@H]([C@@H](O)CCC[C@@H](O)CCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCCCCC=2C(O[C@@H](C)C=2)=O)CC1 DAEFUOXKPZLQMM-AUDZWCKFSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MBABCNBNDNGODA-UHFFFAOYSA-N trilobacin Chemical compound O1C(C(O)CCCCCCCCCC)CCC1C1OC(C(O)CCCCCCCCCCC(O)CC=2C(OC(C)C=2)=O)CC1 MBABCNBNDNGODA-UHFFFAOYSA-N 0.000 description 2
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000722951 Annona Species 0.000 description 1
- 235000007755 Annona Nutrition 0.000 description 1
- 235000011518 Annona purpurea Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- JQOYPOSGHDJFLI-AVNCTIOFSA-N Uvaricin Chemical compound O1[C@@H]([C@@H](OC(C)=O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCCCCC=2C(O[C@@H](C)C=2)=O)CC1 JQOYPOSGHDJFLI-AVNCTIOFSA-N 0.000 description 1
- JQOYPOSGHDJFLI-UHFFFAOYSA-N Uvaricin Natural products O1C(C(OC(C)=O)CCCCCCCCCC)CCC1C1OC(C(O)CCCCCCCCCCCCC=2C(OC(C)C=2)=O)CC1 JQOYPOSGHDJFLI-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Chemical group 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 125000000457 gamma-lactone group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
细胞株 | 本发明药物IC50(μg/mL) | 对照药物Taxol IC50(μg/mL) |
HT-29CNE2SUNE1BEL-7402A-549MCF-7GLC-82 | 0.4464.369×10-21.6173.873×10-24.413×10-31.8573.491 | 0.2954.444×10-30.2209×10-29.846×10-21.373×10-26.058×10-32.091 |
组别 | 给药剂量 给药时间mg/(kg·d) d | 平均抑瘤率( x±s)/% | P值 |
环磷酰胺组CTX本发明药物:剂量组中剂量组1中剂量组2高剂量组 | 18 100.01 100.03 100.06 100.09 10 | 65.80±0.9030.93±0.7344.97±5.1758.26±3.3966.68±5.46 | <0.01<0.01<0.01<0.01<0.01 |
组别 | 给药剂量 给药时间mg/(kg·d) d | 平均抑瘤率( x±s)/% | P值 |
环磷酰胺组CTX本发明药物:低剂量组中剂量组高剂量组 | 18 100.01 100.03 100.09 10 | 56.11±2.5930.93±0.7338.43±2.3550.70±4.08 | <0.01<0.01<0.01<0.01 |
组别 | 给药剂量 给药时间mg/(kg·d) d | 平均抑瘤率( x±s)/% | P值 |
氟脲嘧啶5-Fu本发明药物:低剂量组中剂量组高剂量组 | 30 104 108 1016 10 | 63.30±8.6336.61±3.8746.42±11.3957.53±11.55 | <0.01<0.01<0.01<0.01 |
组别 | 给药剂量 给药时间mg/(kg·d) d | 平均抑瘤率( x±s)/% | P值 |
氟脲嘧啶5-Fu本发明药物:低剂量组中剂量组高剂量组 | 30 104 108 1016 10 | 65.36±15.4735.97±14.7247.46±9.8352.57±11.66 | <0.01<0.01<0.01<0.01 |
组别 | 给药剂量 给药时间mg(kg·d) d | 平均抑瘤率( x±s)/% | P值 |
氟脲嘧啶5-Fu本发明药物:低剂量组中剂量组高剂量组 | 30 104 108 1016 10 | 60.33±0.737.64±0.0146.76±2.1560.75±1.65 | <0.01<0.01<0.01<0.01 |
样品批号 | 含量(质量分数)/% | ||
阿诺宁-1 | 阿诺宁-6 | 阿诺宁-1+阿诺宁-6 | |
981225990108990120 | 52.0651.4253.55 | 10.8811.669.85 | 62.9463.1063.40 |
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011075945A CN1141093C (zh) | 2001-02-27 | 2001-02-27 | 番荔枝内酯抗癌有效部位药及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011075945A CN1141093C (zh) | 2001-02-27 | 2001-02-27 | 番荔枝内酯抗癌有效部位药及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1370530A CN1370530A (zh) | 2002-09-25 |
CN1141093C true CN1141093C (zh) | 2004-03-10 |
Family
ID=4656511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011075945A Expired - Lifetime CN1141093C (zh) | 2001-02-27 | 2001-02-27 | 番荔枝内酯抗癌有效部位药及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1141093C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101375936B (zh) * | 2007-08-29 | 2012-02-29 | 北京星昊医药股份有限公司 | 抗肿瘤复方番荔枝制剂及其制备方法 |
CN101575324B (zh) * | 2009-05-15 | 2011-05-25 | 贵州正鑫药业有限公司 | 一种从番荔枝中提取抗癌有效部位药史可莫辛的制备方法 |
CN109528785A (zh) * | 2019-01-31 | 2019-03-29 | 中国医学科学院药用植物研究所 | 一种对耐药肿瘤选择性杀伤或nM水平高效杀伤的药物组合物及其应用 |
CN110526883A (zh) * | 2019-07-22 | 2019-12-03 | 苏州农业职业技术学院 | 一种从番荔枝种子中提取泡番荔枝辛的方法 |
-
2001
- 2001-02-27 CN CNB011075945A patent/CN1141093C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1370530A (zh) | 2002-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101904968B (zh) | 重楼薯蓣类皂苷的制备方法及其抗肿瘤药物制剂 | |
CN102652792A (zh) | 包含大蒜油、大蒜总多糖和大蒜总皂苷的组合物的抗癌用途 | |
Hajimehdipoor et al. | The cytotoxic effects of Ferula persica var. persica and Ferula hezarlalehzarica against HepG2, A549, HT29, MCF7 and MDBK cell lines | |
CN105017345B (zh) | 从夏枯草中同时提取四种化合物的方法及应用 | |
CN101979366A (zh) | 莪术中的二苯庚烷类化合物及其医药用途 | |
CN101485700B (zh) | 抗肿瘤活性精制番荔枝总内酯及其制备方法 | |
CN1141093C (zh) | 番荔枝内酯抗癌有效部位药及其制备方法 | |
CN1247855A (zh) | 丹参多酚酸盐的制备方法和用途 | |
CN102827001A (zh) | 一种苦丁茶冬青提取物 | |
CN102908340B (zh) | 一种含异甘草黄酮醇的抗肿瘤药物及其应用 | |
Altinyay et al. | Quantification of shikimic acid in the methanolic extracts of three alnus taxons growing in Turkey | |
Hajimehdipoor et al. | The Cytotoxic Effects of Ferula Persica var. Persica and Ferula Hezarlalehzarica against HepG2, A549, HT29, MCF7 and MDBK Cell Lines: Cytotoxicity of Ferula species | |
CN103833823A (zh) | 二萜二聚体类化合物及其药物组合物和制备方法与应用 | |
CN101721434B (zh) | 一种阿里红有效组分及其制备方法和用途 | |
CN1165545C (zh) | 从栾树植物中分离提取总黄酮部位的方法及其应用 | |
CN102961440A (zh) | 含有人环氧酶及天然阿霉素或类阿霉素的药用组合物、其制备方法及在制备多种药物的应用 | |
CN102805829B (zh) | 土茯苓提取物的制备方法及其在肿瘤治疗中的应用 | |
CN104374890B (zh) | 一种苦丁茶冬青提取物 | |
CN106008641A (zh) | 睡茄交酯类化合物及提取方法及用途 | |
CN104546952A (zh) | 一种石上柏活性组分及其制备方法和用途 | |
CN111978309B (zh) | 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂 | |
CN105796548B (zh) | 一种黄酮类药物组合物及制备方法和用途 | |
CN102114065B (zh) | 具有防治癌症作用的金钱草与雷公藤中药组合物及其应用 | |
CN1068782C (zh) | 以栾树提取物为有效组分的抗癌药物及制备方法 | |
CN104288169B (zh) | 一种黄酮苷类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: GUILIN SANJIN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: SOUTH CHINA BOTANICAL GARDEN CHINESE ACADEMY OF SCIENCES Owner name: SOUTH CHINA BOTANICAL GARDEN CHINESE ACADEMY OF SC Free format text: FORMER NAME OR ADDRESS: SOUTH-CHINA INST. OF BOTANY, CHINESE ACADEMY OF SCIENCES |
|
CP03 | Change of name, title or address |
Address after: No. 1, Jinxing Road, Guilin, the Guangxi Zhuang Autonomous Region: 541004 Patentee after: GUILIN SANJIN PHARMACEUTICAL Co.,Ltd. Address before: Guangdong city of Guangzhou province Shahe Chang ban happy home zip code: 510650 Patentee before: South China Botanical Garden, Chinese Academy of Sciences Address after: Guangdong city of Guangzhou province Shahe Chang ban happy home zip code: 510650 Patentee after: SOUTH CHINA BOTANICAL GARDEN, CHINESE ACADEMY OF SCIENCES Address before: Guangdong city of Guangzhou province Shahe Chang ban happy home zip code: 510650 Patentee before: SOUTH CHINA INST OF BOTANY CHI |
|
CX01 | Expiry of patent term |
Granted publication date: 20040310 |
|
CX01 | Expiry of patent term | ||
DD01 | Delivery of document by public notice |
Addressee: Xiong Qiling Document name: Notice of termination of patent right |
|
DD01 | Delivery of document by public notice |